DANA POINT, Calif., Dec. 30, 2014 (GLOBE NEWSWIRE) -- HemoLife Medical is pleased to announce the global market launch of its revolutionary I.M.P.A.C.T. System® in the European Union, Asia-Pacific and Canada. The I.M.P.A.C.T. System® device is registered, or in the process of registration in 32 geographies worldwide. Initial product shipments to the European Union and to Asia-Pacific are in progess, with patient treatments beginning in January 2015.
The I.M.P.A.C.T. System® is an innovative extractive therapy device for the detoxification of plasma in inflammatory-mediated conditions such as severe Sepsis and Hepatic Encephalopathy, globally costing more than $90 billion a year. Beginning in 2015, the world will have a new standard of care for treating Sepsis and liver disease, potentially saving millions of lives and billions of dollars.
Lon Stone, HemoLife Medical's CEO added, "This event is the culmination of endless hours and years of disease progression understanding, product research and development, successful and dramatic patient clinical evaluations, attracting an experienced professional leadership team, global product registrations and the development of our distribution network. Positive patient and economic outcomes will result in a positive revenue outcome for HemoLife Medical."
HemoLife Medical, Inc. is a privately held company focused on the development of innovative medical devices and protocols intended to improve the patient condition for those suffering from liver disease and severe systemic inflammatory conditions.
CONTACT: HemoLife Medical, Inc. info@HemoLifeMedical.com +1-844-HEMOLIFE
Source: HemoLife Medical